CRDL

Cardiol Therapeutics
CRDL
Market cap $124M

1.78 USD

-0.05

2.73%

At close Oct 10, 4:00 PM EDT

After hours

1.82

+0.04

2.25%

1 day

-2.73%

5 days

-8.25%

1 month

-14.83%

3 months

-12.32%

6 months

-4.81%

Year to date

102.27%

1 year

94.56%

5 years

-25.52%

About: Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Employees: 17

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

4,883% more call options, than puts

Call options by funds: $897K | Put options by funds: $18K

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

14% more funds holding

Funds holding: 35 [Q1] → 40 (+5) [Q2]

2.25% less ownership

Funds ownership: 10.07% [Q1] → 7.81% (-2.25%) [Q2]

8% less capital invested

Capital invested by funds: $11.7M [Q1] → $10.8M (-$908K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CRDL.

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about CRDL published over the past 30 days

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfully closed its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million, before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering. As previously stated, the Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Proactive Investors

Cardiol Therapeutics prices $13.5M public offering

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL), a clinical-stage life sciences company focused on heart disease treatments, announced on Wednesday it is raising US$13.5 million through a public offering of 8,437,500 Class A common shares priced at $1.60 per share. The company said it plans to use the net proceeds from the offering to advance the clinical development of its lead product, CardiolRx, for the treatment of recurrent pericarditis, a condition involving inflammation of the heart's outer lining.

Cardiol Therapeutics prices $13.5M public offering

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering. The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Proactive Investors

Cardiol Therapeutics reaches target enrollment for Phase II acute myocarditis trial

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that it has reached its target enrollment of 100 patients in the ARCHER trial, a Phase II randomized, double-blind, placebo-controlled study evaluating CardiolRx for myocardial recovery in patients with acute myocarditis. "We are pleased to have achieved our target patient enrollment in the ARCHER trial, which reflects the commitment and dedication of our clinical collaborators and participating patients," said Andrew Hamer, chief medical officer at Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL).

Cardiol Therapeutics reaches target enrollment for Phase II acute myocarditis trial

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced it has achieved the target patient enrollment of 100 patients in "ARCHER", its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx™ on myocardial recovery in patients with acute myocarditis. "We are pleased to have achieved our target patient enrollment in the ARCHER trial, which reflects the commitment and dedication of our clinical collaborators and participating patients.

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Proactive Investors

Cardiol Therapeutics to unveil data from Phase 2 recurrent pericarditis study

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that it has completed its Phase 2 MAvERIC-Pilot study investigating the impact of its novel therapy CardiolRx in patients with recurrent pericarditis and it will be presenting the results at American Heart Association Scientific Sessions 2024. The company said full clinical data from the trial will be reported during an oral presentation at the event on Monday, November 18, 2024, starting at 9:45am.

Cardiol Therapeutics to unveil data from Phase 2 recurrent pericarditis study

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024 Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture that runs from 9:45 a.m. to 11:00 a.m.

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General and Special Meeting of Shareholders (the "AGM") will be webcast on June 26, 2024, at 4:30 p.m. EDT. Cardiol Therapeutics 2024 AGM When: June 26, 2024, at 4:30 p.m.

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

See News Rankings

Charts implemented using Lightweight Charts™